Brief: AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer
08/11/2023 13:48
Nov 8 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH ANNOUNCES ENCOURAGING TRANSLATIONAL DATA
FROM
PHASE 2 STUDY EVALUATING AMPLIGEN® FOR THE TREATMENT OF ADVANCED
RECURRENT OVARIAN CANCER
* AIM IMMUNOTECH INC: PHASE 2 STUDY ONGOING; TOPLINE INTERIM
RESULTS EXPECTED BEFORE YEAR END
* AIM IMMUNOTECH INC: HOPE TO ANNOUNCE TOPLINE INTERIM
SURVIVAL
RESULTS FROM UPMC IN NEAR FUTURE.
Source text for Eikon: ID:nGNX2r9c7N
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential